INT16478

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 1987
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 29
Total Number 31
Disease Relevance 18.07
Pain Relevance 4.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plg) extracellular space (Plg) extracellular region (Plg)
Anatomy Link Frequency
platelet 2
plasma 1
eyes 1
stromal cells 1
body 1
Plg (Mus musculus)
Pain Link Frequency Relevance Heat
Kinase C 15 100.00 Very High Very High Very High
Infliximab 8 99.60 Very High Very High Very High
Inflammation 174 99.32 Very High Very High Very High
metalloproteinase 62 99.12 Very High Very High Very High
Angina 12 95.44 Very High Very High Very High
long-term potentiation 2 95.28 Very High Very High Very High
IPN 5 94.88 High High
cva 168 93.20 High High
Analgesic 8 92.00 High High
Inflammatory response 10 88.36 High High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 210 100.00 Very High Very High Very High
Pyoderma Gangrenosum 140 100.00 Very High Very High Very High
Impulse Control Disorders 82 100.00 Very High Very High Very High
Bacterial Infection 2 99.84 Very High Very High Very High
Disease 189 99.64 Very High Very High Very High
Inflammatory Bowel Disease 23 99.32 Very High Very High Very High
Necrosis 28 99.06 Very High Very High Very High
Cancer 244 98.88 Very High Very High Very High
Endotoxemia 21 98.76 Very High Very High Very High
Embolism 128 98.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Importantly, polymorphisms in the u-PA gene have been proposed to be associated with late-onset AD, suggesting that deregulation of the plasminogen system may be associated with the pathogenesis of the disease [12].
Positive_regulation (deregulation) of plasminogen system associated with disease
1) Confidence 0.45 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604890 Disease Relevance 0.55 Pain Relevance 0.05
Resveratrol, SIRT1, and plasmin activation
Positive_regulation (activation) of plasmin
2) Confidence 0.41 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604890 Disease Relevance 0.37 Pain Relevance 0.07
Because plasminogen is activated on the surface of cells and the embolus, this compound enabled local amplification of plasmin at the sites where it was needed.
Positive_regulation (activated) of plasminogen associated with embolism
3) Confidence 0.20 Published 2010 Journal Naunyn Schmiedebergs Arch Pharmacol Section Body Doc Link PMC2926440 Disease Relevance 0.70 Pain Relevance 0.23
Because plasminogen is activated on the surface of cells and the embolus, the effect of SMTP-7 is based on a physiological process.
Positive_regulation (activated) of plasminogen associated with embolism
4) Confidence 0.20 Published 2010 Journal Naunyn Schmiedebergs Arch Pharmacol Section Body Doc Link PMC2926440 Disease Relevance 0.67 Pain Relevance 0.24
In our study, retinal occludin content in STZ-induced diabetic rats was preserved in eyes receiving rAAV-angiostatin as compared to eyes receiving rAAV-lacZ.
Positive_regulation (induced) of angiostatin in eyes associated with diabetes mellitus
5) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2533034 Disease Relevance 0.92 Pain Relevance 0.04
In particular, Stachybotrys microspora triprenyl phenol-7 (SMTP-7; Orniplabin, MW 869.1, Fig. 1) is five to ten times more potent than staplabin in enhancing plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation (Hu et al. 2000).
Positive_regulation (activation) of plasminogen
6) Confidence 0.14 Published 2010 Journal Naunyn Schmiedebergs Arch Pharmacol Section Body Doc Link PMC2926440 Disease Relevance 0.65 Pain Relevance 0.03
SMTP-7 promotes conversion to plasmin by a conformational change of plasminogen with a plasminogen activator (Koyama et al. 1997).
Positive_regulation (change) of plasminogen
7) Confidence 0.14 Published 2010 Journal Naunyn Schmiedebergs Arch Pharmacol Section Body Doc Link PMC2926440 Disease Relevance 0.61 Pain Relevance 0.20
SMTP-7 promotes conversion to plasmin by a conformational change of plasminogen with a plasminogen activator (Koyama et al. 1997).
Positive_regulation (activator) of plasminogen
8) Confidence 0.14 Published 2010 Journal Naunyn Schmiedebergs Arch Pharmacol Section Body Doc Link PMC2926440 Disease Relevance 0.62 Pain Relevance 0.20
The triprenyl phenol staplabin (Shinohara et al. 1996) is the first low-molecular-weight compound that enhances both plasminogen–fibrin binding and the activation of plasminogen by relaxing the plasminogen conformation (Takayasu et al. 1997).
Positive_regulation (activation) of plasminogen
9) Confidence 0.13 Published 2010 Journal Naunyn Schmiedebergs Arch Pharmacol Section Body Doc Link PMC2926440 Disease Relevance 0.09 Pain Relevance 0.05
Although increased levels of plasminogen activators such as tissue plasminogen activator (t-PA) have been observed in sepsis [27], their action appears to be counterbalanced by increased PAI-1 levels, resulting in ineffective fibrinolysis and enhanced organ damage [28].
Positive_regulation (activators) of plasminogen associated with sepsis
10) Confidence 0.07 Published 2006 Journal Crit Care Section Body Doc Link PMC1751084 Disease Relevance 0.95 Pain Relevance 0
The receptor (u-PAR/CD87) focuses the enzymatic activity of u-PA and allows activation of plasminogen (PG) at the cell surface, which in turn, is bound to the cell membrane by ?
Positive_regulation (activation) of plasminogen
11) Confidence 0.06 Published 2004 Journal Reprod Biol Endocrinol Section Body Doc Link PMC320496 Disease Relevance 0.53 Pain Relevance 0.06
The fibrinolytic activities of compound 1 and 2 were investigated by the reciprocal activation of single chain urokinase-type plasminogen activator (pro-u-PA) and plasminogen.
Spec (investigated) Positive_regulation (activation) of plasminogen
12) Confidence 0.06 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707035 Disease Relevance 0 Pain Relevance 0
The fibrinolytic activities of compound 1 and 2 were investigated by the reciprocal activation of single chain urokinase-type plasminogen activator (pro-u-PA) and plasminogen.
Spec (investigated) Positive_regulation (activation) of plasminogen
13) Confidence 0.05 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707035 Disease Relevance 0 Pain Relevance 0
S. fulvellum was selected by a screening of approximately 700 of plant extracts for compounds that enhance reciprocal activation of pro-u-PA and plasminogen.
Positive_regulation (activation) of plasminogen
14) Confidence 0.05 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707035 Disease Relevance 0.15 Pain Relevance 0.10
According to our knowledge, this is the first time to isolate MOGG from marine lives and discover that POGG and MOGG enhanced reciprocal activation of pro-u-PA and plasminogen in vitro.

4.

Positive_regulation (activation) of plasminogen
15) Confidence 0.05 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707035 Disease Relevance 0.09 Pain Relevance 0.14
The changes and our interpretation of them include the following: 1) the elevation of thrombin antithrombin III complex levels (activation of blood coagulation) was transient and monophasic; 2) the elevation of plasmin alpha 2-antiplasmin complex and D-dimer levels (activation of fibrinolysis) was biphasic, despite the monophasic elevation of tissue plasminogen activator or plasminogen activator inhibitor-1 levels; 3) the elevation of beta-thromboglobulin and platelet-factor-4 levels (activation of platelet) was also biphasic; 4) fibrinogen level and alpha 2-antiplasmin activity increased in the acute phase of the postoperative course (acute phase reaction); 5) the changes in hematocrit appeared to parallel those in various other parameters, especially platelet count, antithrombin III, and plasminogen levels for 1 or 2 days after surgery; 6) fibronectin appeared to be consumed in the acute phase of postoperative course; and 7) general anesthesia did not significantly affect hemostasis.
Positive_regulation (elevation) of plasminogen in platelet associated with anesthesia and acute-phase reaction
16) Confidence 0.05 Published 1994 Journal Neurosurgery Section Abstract Doc Link 7936148 Disease Relevance 0.17 Pain Relevance 0.16
The changes and our interpretation of them include the following: 1) the elevation of thrombin antithrombin III complex levels (activation of blood coagulation) was transient and monophasic; 2) the elevation of plasmin alpha 2-antiplasmin complex and D-dimer levels (activation of fibrinolysis) was biphasic, despite the monophasic elevation of tissue plasminogen activator or plasminogen activator inhibitor-1 levels; 3) the elevation of beta-thromboglobulin and platelet-factor-4 levels (activation of platelet) was also biphasic; 4) fibrinogen level and alpha 2-antiplasmin activity increased in the acute phase of the postoperative course (acute phase reaction); 5) the changes in hematocrit appeared to parallel those in various other parameters, especially platelet count, antithrombin III, and plasminogen levels for 1 or 2 days after surgery; 6) fibronectin appeared to be consumed in the acute phase of postoperative course; and 7) general anesthesia did not significantly affect hemostasis.
Positive_regulation (elevation) of plasminogen in platelet associated with anesthesia and acute-phase reaction
17) Confidence 0.04 Published 1994 Journal Neurosurgery Section Abstract Doc Link 7936148 Disease Relevance 0.17 Pain Relevance 0.16
It was shown that PV-IgG caused a rapid, transient phospholipase C (PLC)-dependent increase of inositol 1,4,5 trisphosphate and of intracellular Ca2+ leading to activation of both PKC and plasminogen activator (PA) (Esaki et al. 1995; Kitajima et al. 1999; Memar et al. 1996; Osada et al. 1997; Seishima et al. 1995, 1999).
Positive_regulation (activation) of plasminogen associated with kinase c and bullous skin disease
18) Confidence 0.04 Published 2008 Journal Histochem Cell Biol Section Body Doc Link PMC2413110 Disease Relevance 0.72 Pain Relevance 0.17
Proteases involved in these processes include serine proteases (the plasminogen activators uPA and tPA), matrix metalloproteinases (MMPs), and cysteine proteases (cathepsins B, D, L and H) [12].
Positive_regulation (activators) of plasminogen associated with metalloproteinase
19) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2904700 Disease Relevance 1.44 Pain Relevance 0.21
With its "clot-selectivity", t-PA is capable of lysing clots without having a significant effect on circulating plasminogen.
Positive_regulation (circulating) of plasminogen
20) Confidence 0.03 Published 1987 Journal Pharmacotherapy Section Abstract Doc Link 3120160 Disease Relevance 0.31 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox